|
Dr. Mohammad Ali Amini
Chief Executive Officer & Co-Founder DVM, Phd in Pharmaceutical Oncology Serial entrepreneur and the former CEO of SmartPath Over 10 years of experience in Drug Development and 3 years in Clinical Practice |
|
Dr. Shirley Wu
Chief Scientific Officer & Co-Founder PhD, Professor, FAAPS Director of Advanced Pharmaceutics Laboratory Leslie Dan Faculty of Pharmacy, University of Toronto |
|
Dr. Azhar Zahoor Abbasi
Exec. VP of R&D PhD in Physical Chemistry Former Apotex Scientist Expert in Product QC and Product Development |
|
Dr. Chanson (Chunsheng) He
Exec. VP of Operations PhD in Organic Chemistry Years of industrial experience, expertise in Formulation Development and Scale-up |
|
Dr. John Reid
Exec. VP of Business Development PhD, MBA Former Director of Strategic Partnering / Molecular Sciences, AstraZeneca USA Former Director of Technology Development and Commercialization at UHN. |
ADVISORS
Dr. Michael Milosevic
BASc, Engineering, MD, Radiation Oncology (FRCPC)
Vice Chair (Research), Department of Radiation Oncology, University of Toronto
Professor, Department of Radiation Oncology, University of Toronto
Director of Research, Radiation Medicine Program, Princess Margaret Cancer Centre/University Health Network, Toronto
Gynecologic Cancer Site Lead, Radiation Medicine Program, Princess Margaret Hospital/University Health Network, Toronto
Lead, MR-Guided Adaptive Radiotherapy Program, Princess Margaret Hospital/University Health Network, Toronto
Lead, MR-Guided Brachytherapy Program, Princess Margaret Hospital/University Health Network, Toronto
Co-Chair, Cancer Care Ontario GYN Radiation Oncology Community of Practice
Chair, Canadian Partnership for Quality Radiotherapy (CPQR)
BASc, Engineering, MD, Radiation Oncology (FRCPC)
Vice Chair (Research), Department of Radiation Oncology, University of Toronto
Professor, Department of Radiation Oncology, University of Toronto
Director of Research, Radiation Medicine Program, Princess Margaret Cancer Centre/University Health Network, Toronto
Gynecologic Cancer Site Lead, Radiation Medicine Program, Princess Margaret Hospital/University Health Network, Toronto
Lead, MR-Guided Adaptive Radiotherapy Program, Princess Margaret Hospital/University Health Network, Toronto
Lead, MR-Guided Brachytherapy Program, Princess Margaret Hospital/University Health Network, Toronto
Co-Chair, Cancer Care Ontario GYN Radiation Oncology Community of Practice
Chair, Canadian Partnership for Quality Radiotherapy (CPQR)
Dr. Masoom Haider
BAM, MD, FRCPC
Director of the Sinai Health Research MRI
Head of the Radiomics and Oncologic Imaging Research Lab at Mount Sinai Hospital.
Staff Radiologist, Mount Sinai Hospital, Senior Clinician Scientist, LTRI and Professor, Department of Medical Imaging, University of Toronto
Associate Vice Chair of the Biomarkers, Radiomics, Quantitation, Theranostics Group, Medical Imaging, Faculty of Medicine, University of Toronto.
BAM, MD, FRCPC
Director of the Sinai Health Research MRI
Head of the Radiomics and Oncologic Imaging Research Lab at Mount Sinai Hospital.
Staff Radiologist, Mount Sinai Hospital, Senior Clinician Scientist, LTRI and Professor, Department of Medical Imaging, University of Toronto
Associate Vice Chair of the Biomarkers, Radiomics, Quantitation, Theranostics Group, Medical Imaging, Faculty of Medicine, University of Toronto.
